NexMed Announces The Expansion Of Its Senior Management Team
NexMed, Inc. (NASDAQ: NEXM), a specialty CRO with a pipeline of products based on the NexACT ® technology, announced today announced the expansion of its senior management team within its operating subsidiaries, with the appointment of Terry Ladd as Vice-President of Business Development at Bio-Quant, Inc. and Richard Martin, Ph.D., as Vice President of Chemistry for NexMed (U.S.A.), Inc. Both executives will report to Dr. Bassam Damaj, President and Chief Executive Officer of NexMed, Inc.
In his new position, effective April 12, 2010, Mr. Ladd will be responsible for the worldwide business development operations of Bio-Quant, NexMed’s discovery pre-clinical service subsidiary. Mr. Ladd brings more than 20 years of sales experience in the preclinical field, including senior management positions in sales and marketing with Calvert Laboratories, Inc., MDS Pharma Services, Inc., SkeleTech, Inc., Phoenix International Life Sciences, Inc., Chrysalis International, Inc., Pharmakon Research International, Inc., and ITR Laboratories, Inc. Mr. Ladd holds an M.B.A. in Marketing and Finance from McGill University, an M.A. from the University of Sherbrooke, and a B.A. Honors degree from Bishop’s University.
As Vice President of Chemistry, effective immediately, Dr. Martin is leading the development work for the next generation of NexACT technology and NexACT-based products at NexMed (U.S.A.). Dr. Martin has over 20 years of medicinal chemistry research and development experience in the fields of antibacterial, inflammation, oncology, antiviral, cardiovascular and metabolic diseases. Prior to joining NexMed (U.S.A.), Dr. Martin was Senior Director of Chemistry at RetroVirox, Inc. a privately-held biotechnology company engaged in the discovery of new treatments for patients with infectious diseases. Dr. Martin also served as Director of Chemistry at Exelixis, Inc./X-Ceptor Therapeutics, Inc. and Group Leader at Tanabe Research Laboratories U.S.A., Inc. in San Diego -- a wholly owned subsidiary of Mitsubishi-Tanabe in Japan. Dr. Martin received his Ph.D. in Organic Chemistry from the University of Toronto and completed his postdoctoral research at The Scripps Research Institute in San Diego. Dr. Martin holds over 20 patents and patent applications and has authored/co-authored over 20 papers.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV